LAB - Standard BioTools Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Current Price & Safety Score Price: 0.61 USD StockBonds Safety Grade: D Altman Z-Score (Bankruptcy Risk): -0.46 StockBond Score: -6.16 Company Description Standard BioTools Inc together with its subsidiaries develops manufactures and sells a range of instrumentation consumables and services to scientists and biomedical researchers to develop therapeutics in the Americas Europe the Middle East Africa and the Asia pacific The company operates through Proteomics and Genomics segments Its proteomics and genomics include instruments consumables and assays for clinical and diagnostic uses The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms CyTOF technology platform that uses metaltagged antibodies and timeofflight mass spectrometry to eliminate signal interference and expand multiplexing capabilities Hyperion a spatial biology platform which unlocks deeper insights into tissue organization by preserving spatial context while enabling highdimensional molecular and proteomic analysis and Biomark X9 system that redefines highthroughput genomics for quantitative polymerase chain reaction applications The company sells its instruments and consumables for research use only to academic research institutions translational research and medicine centers cancer centers and clinical research laboratories as well as biopharmaceutical biotechnology and plant and animal research companies It has license agreements with California Institute of Technology Harvard University and Caliper Life Sciences Inc The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc in November 2001 Standard BioTools Inc was incorporated in 1999 and is headquartered in Boston Massachusetts